ACCESS DB # _____

FOR OFFICIAL USE ONLY *PLEASE PRINT CLEARLY*

Scientific and Technical Information Center

SEARCH REQUEST FORM

Requester's Full Name: Kahsay Habte Examiner #: 78271 Date: 6/29/05

Art Unit: 1624 Phone Number: 2- Serial Number: 10/705,446

Location (Bldg/Room#): SC-15 (Mailbox #): SC-18 Results Format Preferred (circle): PAPER DISK

****

To ensure an efficient and quality search, please attach a copy of the cover sheet, claims, and abstract or fill out the following:

Title of Invention: _____

Inventors (please provide full names): _____

_____

Earliest Priority Date: _____

Search Topic:

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc., if known.

For Sequence Searches Only* *Please include all pertinent information (including parent, child or divisional application numbers) along with the appropriate serial number.



V



II



III

W = N



IV



EX



VIII



VII



XI

Please search the following core structures (pyridine fused to N-containing 5-membered ring)

X = C, W = N in formula III

A & B may form Carbocycle; A & R^2, B & R^2 may form a ring

Please see attached for more info

****

STAFF USE ONLY

Searcher: _____

Searcher Phone #: _____

Searcher Location: _____

Date Searcher Picked Up: _____

Date Completed: _____

Searcher Prep & Review Time: _____

Online Time: _____

Type of Search

_____ NA Sequence (#)

_____ AA Sequence (#)

_____ Structure (#)

_____ Bibliographic

_____ Litigation

_____ Fulltext

_____ Other

Vendors and cost where applicable

_____ STN _____ Dialog

_____ Questel/Orbit _____ Lexis/Nexis

_____ Westlaw _____ WWW/Internet

____ In-house sequence systems

____ Commercial ____ Oligomer ____ Score/Length

____ Interference ____ SPDI ____ Encode/Transl

_____ Other (specify)

Application

L5 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:247338 HCAPLUS
DOCUMENT NUMBER: 134:280854
ENTRY DATE: Entered STN: 06 Apr 2001
TITLE: Preparation of certain alkylene diamine-substituted heterocycles as NPY1 receptor inhibitors
INVENTOR(S): Horvath, Raymond F.; Tran, Jennifer; De, Lombaert Stephane; Hodgetts, Kevin Julian; Carpino, Philip A.; Griffith, David A.
PATENT ASSIGNEE(S): Neurogen Corporation, USA; Pfizer, Inc.; De Lombaert, Stephane
SOURCE: PCT Int. Appl., 211 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
INT. PATENT CLASSIF.:
MAIN: C07D487-04
SECONDARY: A61K031-519; A61K031-437; A61K031-4365; A61K031-47; A61K031-44; A61P009-00; A61P025-00; C07D471-04; C07D473-34; C07D215-46; C07D213-73; C07D239-48; C07D471-14; C07D495-04; C07D475-08; G01N033-566; C07D487-04; C07D239-00; C07D209-00
CLASSIFICATION: 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2001023389	A2	20010405	WO 2000-US26886		20000929
WO 2001023389	A3	20020510			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
CA 2379640	AA	20010405	CA 2000-2379640		20000929
EP 1224187	A2	20020724	EP 2000-967133		20000929
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL					
US 6506762	B1	20030114	US 2000-676941		20000929
JP 2003510327	T2	20030318	JP 2001-526541		20000929
NZ 517575	A	20040430	NZ 2000-517575		20000929
BG 106508	A	20030228	BG 2002-106508		20020311
NO 2002001358	A	20020527	NO 2002-1358		20020319
ZA 2002002518	A	20030630	ZA 2002-2518		20020328
US 2003158197	A1	20030821	US 2002-291446		20021108
US 6696445	B2	20040224			
US 2004229870	A1	20041118	US 2003-705446		20031110 <--
PRIORITY APPLN. INFO.:			US 1999-156870P	P	19990930
			US 2000-676941	A3	20000929
			WO 2000-US26886	W	20000929

US 2002-291446 A3 20021108

PATENT CLASSIFICATION CODES:

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2001023389	ICM	C07D487-04
	ICS	A61K031-519; A61K031-437; A61K031-4365; A61K031-47; A61K031-44; A61P009-00; A61P025-00; C07D471-04; C07D473-34; C07D215-46; C07D213-73; C07D239-48; C07D471-14; C07D495-04; C07D475-08; G01N033-566; C07D487-04; C07D239-00; C07D209-00
WO 2001023389	ECLA	C07D213/73F6; C07D215/46; C07D239/48B1; C07D471/04+221B+209B; C07D471/04+235B+221B; C07D471/04+249B+221B; C07D471/04+241B+221B; C07D471/14+221C+221B+209C; C07D471/14+239B+221C+209C; C07D473/34; C07D475/08; C07D487/04+239B+209B; C07D487/04+239B+231B; C07D487/04+239C+235C; C07D487/04+239C+209C; C07D487/04+251C+209C; C07D495/04+333B+239B; C07D495/04+333B+221B
US 6506762	NCL	514/259.400; 514/259.410; 514/263.200; 514/263.210; 514/263.220; 514/263.230; 514/263.400; 514/264.110; 514/265.100; 544/080.000; 544/236.000; 544/254.000; 544/256.000; 544/257.000; 544/262.000; 544/276.000; 544/277.000; 544/278.000; 544/279.000; 544/281.000; 544/282.000
	ECLA	C07D213/73F6; C07D215/46; C07D239/48B1; C07D471/04+221B+209B; C07D471/04+235B+221B; C07D471/04+241B+221B; C07D471/04+249B+221B; C07D471/14+221C+221B+209C; C07D471/14+239B+221C+209C; C07D473/34; C07D475/08; C07D487/04+239C+209C; C07D487/04+239C+235C; C07D487/04+239B+231B; C07D487/04+239B+209B; C07D487/04+251C+209C; C07D495/04+333B+221B; C07D495/04+333B+239B
US 2003158197	NCL	514/245.000; 544/196.000; 544/197.000; 544/198.000; 544/199.000; 544/208.000; 544/209.000; 544/210.000
	ECLA	C07D213/73F6; C07D473/34; C07D475/08; C07D487/04+239C+209C; C07D487/04+239C+235C; C07D487/04+239B+231B; C07D487/04+239B+209B; C07D487/04+251C+209C; C07D495/04+333B+221B; C07D495/04+333B+239B; C07D215/46; C07D239/48B1; C07D471/04+221B+209B; C07D471/04+235B+221B; C07D471/04+241B+221B; C07D471/04+249B+221B; C07D471/14+221C+221B+209C; C07D471/14+239B+221C+209C
US 2004229870	NCL	514/229.500; 514/246.000; 514/251.000; 514/262.100; 514/261.100; 514/263.300; 514/265.100; 544/063.000; 544/182.000; 544/254.000
	ECLA	C07D213/73F6; C07D215/46; C07D239/48B1; C07D471/04+221B+209B; C07D471/04+235B+221B; C07D471/04+241B+221B; C07D471/04+249B+221B; C07D471/14+221C+221B+209C; C07D471/14+239B+221C+209C; C07D473/34; C07D475/08; C07D487/04+239B+209B; C07D487/04+239B+231B; C07D487/04+239C+209C; C07D487/04+239C+235C; C07D487/04+251C+209C; C07D495/04+333B+221B; C07D495/04+333B+239B <--

OTHER SOURCE(S): MARPAT 134:280854

GRAPHIC IMAGE:

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

ABSTRACT:
The title compds. [I-III, etc.; X = N, CR14; W = S, O, NR15; Y = N, CR3; E, F, G = CR3, N; R1 = H, alkyl, etc.; R2 = H, alkyl, cycloalkyl, etc.; A = (un)substituted (CH2)m (wherein m = 1-3); A and B form a (un)substituted carbocycle; A and R2, or B and R2 form (un)substituted aminocarbocycle, aminoheterocycle; B = (un)substituted (CH2)n (n = 1-3); R3, R16 = H, alkyl, etc.; R4 = (un)substituted aryl, heteroaryl; R5 = (cycloalkyl)alkyl, alkenyl, etc.; R6 = H, alkyl, etc.] which are potent antagonists at the NPY1 receptor, and are useful in treating physiol. disorders associated with an excess of neuropeptide Y, including eating disorders, such as, for example, obesity and bulimia, and certain cardiovascular diseases, for example, hypertension, were prepared E.g., a multi-step synthesis of IV was described. The compds. I showed Ki of 0.1 nM - 10 μM against NPY1 receptor binding.

SUPPL. TERM: heterocycle nitrogen contg alkylenediamino substituted prepn neuropeptide Y1 inhibitor; antiobesity heterocycle nitrogen contg alkylenediamino substituted prepn

INDEX TERM: Neuropeptide Y receptors
ROLE: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study)
(Y1; preparation of certain alkylene diamine-substituted heterocycles as NPY1 receptor inhibitors)

INDEX TERM: Heterocyclic compounds
ROLE: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(nitrogen; preparation of certain alkylene diamine-substituted heterocycles as NPY1 receptor inhibitors)

INDEX TERM: Antiobesity agents
(preparation of certain alkylene diamine-substituted heterocycles as NPY1 receptor inhibitors)

INDEX TERM:
332140-74-6P 332140-75-7P 332140-76-8P 332140-82-6P
332140-83-7P 332140-84-8P 332140-85-9P 332140-86-0P
332140-87-1P 332140-88-2P 332140-89-3P 332140-90-6P
332140-91-7P 332140-92-8P 332140-93-9P 332140-94-0P
332140-95-1P **332140-96-2P** **332140-97-3P**
332140-98-4P **332140-99-5P** 332141-00-1P
332141-01-2P 332141-02-3P 332141-03-4P
332141-04-5P **332141-05-6P**
332141-06-7P **332141-07-8P** 332141-08-9P
332141-09-0P 332141-10-3P 332141-11-4P 332141-12-5P
332141-13-6P 332141-14-7P 332141-15-8P 332141-17-0P
332141-18-1P 332141-19-2P 332141-20-5P 332141-21-6P
332141-22-7P 332141-23-8P 332141-24-9P 332141-25-0P
332141-26-1P 332141-27-2P 332141-28-3P
332141-29-4P **332141-30-7P**
332141-31-8P **332141-32-9P** 332141-33-0P
332141-34-1P 332141-35-2P 332141-36-3P
332141-37-4P **332141-38-5P**
332141-39-6P **332141-40-9P** 332141-41-0P
332141-42-1P 332141-43-2P 332141-44-3P
332141-45-4P **332141-46-5P**
332141-47-6P **332141-48-7P** 332141-49-8P
332141-50-1P 332141-51-2P 332141-52-3P

332141-53-4P **332141-54-5P**
332141-56-7P **332141-58-9P** 332141-59-0P
332141-60-3P 332141-61-4P 332141-62-5P 332141-63-6P
332141-64-7P 332141-65-8P 332141-66-9P 332141-67-0P
332141-68-1P 332141-69-2P 332141-70-5P 332141-71-6P
332141-72-7P 332141-73-8P 332141-74-9P 332141-75-0P
332141-76-1P 332141-77-2P 332141-78-3P
332141-79-4P **332141-80-7P**
332141-81-8P **332141-83-0P** 332141-85-2P
332141-86-3P 332141-87-4P 332141-88-5P
332141-89-6P **332141-90-9P**
332141-91-0P **332141-92-1P** 332141-93-2P
332141-94-3P 332141-95-4P 332141-96-5P
332141-97-6P **332141-98-7P**
332141-99-8P **332142-00-4P** 332142-01-5P
332142-02-6P 332142-03-7P 332142-04-8P
332142-05-9P **332142-06-0P**
332142-07-1P **332142-08-2P** 332142-09-3P
332142-10-6P 332142-11-7P 332142-12-8P
332142-13-9P **332142-14-0P**
332142-15-1P **332142-16-2P** 332142-17-3P
332142-18-4P 332142-19-5P 332142-20-8P
332142-21-9P **332142-22-0P**
332142-23-1P **332142-24-2P** 332142-25-3P
332142-26-4P 332142-27-5P 332142-28-6P 332142-29-7P
332142-30-0P 332142-31-1P 332142-32-2P 332142-33-3P
332142-34-4P 332142-35-5P 332142-36-6P 332142-37-7P
332142-38-8P 332142-39-9P 332142-40-2P 332142-41-3P
332142-42-4P 332142-43-5P 332142-44-6P
332142-45-7P **332142-46-8P**
332142-47-9P **332142-48-0P** 332142-49-1P
332142-50-4P 332142-51-5P 332142-52-6P
332142-53-7P **332142-54-8P**
332142-55-9P **332142-56-0P** 332142-57-1P
332142-58-2P 332142-59-3P 332142-60-6P 332142-61-7P
332142-62-8P 332142-63-9P 332142-64-0P 332142-65-1P
332142-66-2P 332142-68-4P 332142-69-5P 332142-70-8P
332142-71-9P 332142-72-0P 332142-73-1P 332142-74-2P
332142-75-3P 332142-76-4P 332142-77-5P 332142-78-6P
332142-79-7P 332142-80-0P 332142-81-1P 332142-82-2P
332142-83-3P 332142-84-4P 332142-85-5P 332142-86-6P
332142-87-7P 332142-88-8P 332142-89-9P 332142-90-2P
332142-91-3P 332142-92-4P 332142-93-5P 332142-94-6P
332142-95-7P 332142-96-8P 332142-97-9P 332142-98-0P
332142-99-1P 332143-00-7P 332143-01-8P 332143-02-9P
332143-03-0P 332143-04-1P 332143-05-2P 332143-06-3P
332143-07-4P 332143-08-5P 332143-09-6P 332143-10-9P
332143-11-0P 332143-12-1P 332143-13-2P 332143-14-3P
332143-15-4P 332143-16-5P 332143-17-6P
ROLE: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of certain alkylene diamine-substituted heterocycles as NPY1 receptor inhibitors)

INDEX TERM: 332143-18-7P 332143-19-8P 332143-20-1P 332143-21-2P
332143-22-3P 332143-23-4P 332143-24-5P 332143-25-6P
332890-16-1P 332890-18-3P **332890-19-4P**

332890-20-7P 332890-22-9P 332890-24-1P 332890-26-3P
332890-28-5P **332890-30-9P** 332890-32-1P
332890-34-3P 332890-36-5P **332890-38-7P**
332890-40-1P **332890-42-3P** 332890-43-4P
332890-45-6P 332890-47-8P 332890-50-3P 332890-52-5P
332890-54-7P 332890-56-9P **332890-58-1P**
332890-60-5P **332890-63-8P** 332890-65-0P
332890-67-2P 332890-68-3P **332890-70-7P**
332890-72-9P **332890-74-1P** 332890-75-2P
332890-76-3P 332890-78-5P 332890-80-9P 332890-81-0P
332890-82-1P 332890-83-2P **332890-84-3P**
332890-86-5P 332890-87-6P 332890-89-8P 332890-91-2P
332890-93-4P 332890-94-5P 332890-95-6P 332890-97-8P
332890-99-0P 332891-01-7P 332891-03-9P 332891-05-1P
332891-06-2P 332891-08-4P 332891-10-8P 332891-13-1P
332891-15-3P
ROLE: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of certain alkylene diamine-substituted heterocycles as NPY1 receptor inhibitors)

INDEX TERM: 77-76-9, 2,2-Dimethoxypropane 93-40-3, 3,4-Dimethoxyphenylacetic acid 105-36-2, Ethyl bromoacetate 109-04-6, 2-Bromopyridine 120-13-8, 2-(4-Ethoxy-3-methoxyphenyl)acetic acid 530-93-8, 1,2,3,4-Tetrahydro-2-naphthalenone 34688-71-6, 2-(2,4,6-Trimethylphenyl)ethanenitrile 204062-63-5
332140-81-5
ROLE: RCT (Reactant); RACT (Reactant or reagent)
(preparation of certain alkylene diamine-substituted heterocycles as NPY1 receptor inhibitors)

INDEX TERM: 252063-61-9P **252063-62-0P** 252063-63-1P
252063-64-2P 252063-65-3P 332140-77-9P 332140-78-0P
332140-79-1P 332140-80-4P
ROLE: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of certain alkylene diamine-substituted heterocycles as NPY1 receptor inhibitors)

INDEX TERM: 252063-66-4P
ROLE: SPN (Synthetic preparation); PREP (Preparation)
(preparation of certain alkylene diamine-substituted heterocycles as NPY1 receptor inhibitors)

INDEX TERM: 140110-45-8
ROLE: PRP (Properties)
(unclaimed nucleotide sequence; preparation of certain alkylene diamine-substituted heterocycles as NPY1 receptor inhibitors)

IT **332140-96-2P 332140-97-3P 332140-98-4P**
332140-99-5P 332141-04-5P 332141-05-6P
332141-06-7P 332141-07-8P 332141-29-4P
332141-30-7P 332141-31-8P 332141-32-9P
332141-37-4P 332141-38-5P 332141-39-6P
332141-40-9P 332141-45-4P 332141-46-5P
332141-47-6P 332141-48-7P 332141-53-4P
332141-54-5P 332141-56-7P 332141-58-9P
332141-79-4P 332141-80-7P 332141-81-8P
332141-83-0P 332141-89-6P 332141-90-9P

332141-91-0P 332141-92-1P 332141-97-6P
332141-98-7P 332141-99-8P 332142-00-4P
332142-05-9P 332142-06-0P 332142-07-1P
332142-08-2P 332142-13-9P 332142-14-0P
332142-15-1P 332142-16-2P 332142-21-9P
332142-22-0P 332142-23-1P 332142-24-2P
332142-45-7P 332142-46-8P 332142-47-9P
332142-48-0P 332142-53-7P 332142-54-8P
332142-55-9P 332142-56-0P 332890-16-1P
332890-19-4P 332890-30-9P 332890-34-3P
332890-38-7P 332890-42-3P 332890-54-7P
332890-58-1P 332890-63-8P 332890-67-2P
332890-70-7P 332890-74-1P 332890-82-1P
332890-84-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of certain alkylene diamine-substituted heterocycles as NPY1 receptor inhibitors)

RN 332140-96-2 HCAPLUS
CN 1,2-Ethanediamine, N-cyclopentyl-N'-[2,6-dimethyl-1-(2,4,6-trimethylphenyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]- (9CI) (CA INDEX NAME)



RN 332140-97-3 HCAPLUS
CN 1,2-Ethanediamine, N-cyclohexyl-N'-[2,6-dimethyl-1-(2,4,6-trimethylphenyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]- (9CI) (CA INDEX NAME)



RN 332140-98-4 HCAPLUS
CN 1,2-Ethanediamine, N-[2-(3,4-dimethoxyphenyl)ethyl]-N'-[2,6-dimethyl-1-(2,4,6-trimethylphenyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 332140-99-5 HCAPLUS
CN 1,2-Ethanediamine, N-[2,6-dimethyl-1-(2,4,6-trimethylphenyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]-N'-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 332141-04-5 HCAPLUS
CN 1,2-Ethanediamine, N-cyclopentyl-N'-[1-(2,6-dichloro-4-methoxyphenyl)-2,6-dimethyl-1H-pyrrolo[2,3-b]pyridin-4-yl]- (9CI) (CA INDEX NAME)



RN 332141-05-6 HCAPLUS
CN 1,2-Ethanediamine, N-cyclohexyl-N'-[1-(2,6-dichloro-4-methoxyphenyl)-2,6-dimethyl-1H-pyrrolo[2,3-b]pyridin-4-yl]- (9CI) (CA INDEX NAME)



RN 332141-06-7 HCAPLUS
CN 1,2-Ethanediamine, N-[1-(2,6-dichloro-4-methoxyphenyl)-2,6-dimethyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-N'-[2-(3,4-dimethoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 332141-07-8 HCAPLUS
CN 1,2-Ethanediamine, N-[1-(2,6-dichloro-4-methoxyphenyl)-2,6-dimethyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-N'-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 332141-29-4 HCAPLUS
CN 1,2-Ethanediamine, N-cyclopentyl-N'-[3,6-dimethyl-1-(2,4,6-trimethylphenyl)-1H-pyrazolo[3,4-b]pyridin-4-yl]- (9CI) (CA INDEX NAME)



RN 332141-30-7 HCAPLUS
CN 1,2-Ethanediamine, N-cyclohexyl-N'-[3,6-dimethyl-1-(2,4,6-trimethylphenyl)-1H-pyrazolo[3,4-b]pyridin-4-yl]- (9CI) (CA INDEX NAME)



RN 332141-31-8 HCAPLUS
CN 1,2-Ethanediamine, N-[2-(3,4-dimethoxyphenyl)ethyl]-N'-[3,6-dimethyl-1-(2,4,6-trimethylphenyl)-1H-pyrazolo[3,4-b]pyridin-4-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 332141-32-9 HCAPLUS
CN 1,2-Ethanediamine, N-[3,6-dimethyl-1-(2,4,6-trimethylphenyl)-1H-pyrazolo[3,4-b]pyridin-4-yl]-N'-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 332141-37-4 HCAPLUS
CN 1,2-Ethanediamine, N-cyclopentyl-N'-[1-(2,6-dichloro-4-methoxyphenyl)-3,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl]- (9CI) (CA INDEX NAME)



RN 332141-38-5 HCAPLUS
CN 1,2-Ethanediamine, N-cyclohexyl-N'-[1-(2,6-dichloro-4-methoxyphenyl)-3,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl]- (9CI) (CA INDEX NAME)



RN 332141-39-6 HCAPLUS
CN 1,2-Ethanediamine, N-[1-(2,6-dichloro-4-methoxyphenyl)-3,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl]-N'-[2-(3,4-dimethoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 332141-40-9 HCAPLUS
CN 1,2-Ethanediamine, N-[1-(2,6-dichloro-4-methoxyphenyl)-3,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl]-N'-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 332141-45-4 HCAPLUS
CN 1,2-Ethanediamine, N-cyclopentyl-N'-[2,5-dimethyl-3-(2,4,6-trimethylphenyl)-3H-imidazo[4,5-b]pyridin-7-yl]- (9CI) (CA INDEX NAME)



RN 332141-46-5 HCAPLUS
CN 1,2-Ethanediamine, N-cyclohexyl-N'-[2,5-dimethyl-3-(2,4,6-trimethylphenyl)-3H-imidazo[4,5-b]pyridin-7-yl]- (9CI) (CA INDEX NAME)



RN 332141-47-6 HCAPLUS
CN 1,2-Ethanediamine, N-[2-(3,4-dimethoxyphenyl)ethyl]-N'-[2,5-dimethyl-3-(2,4,6-trimethylphenyl)-3H-imidazo[4,5-b]pyridin-7-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 332141-48-7 HCAPLUS
CN 1,2-Ethanediamine, N-[2,5-dimethyl-3-(2,4,6-trimethylphenyl)-3H-imidazo[4,5-b]pyridin-7-yl]-N'-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 332141-53-4 HCAPLUS
CN 1,2-Ethanediamine, N-cyclopentyl-N'-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethyl-3H-imidazo[4,5-b]pyridin-7-yl]- (9CI) (CA INDEX NAME)



RN 332141-54-5 HCAPLUS
CN 1,2-Ethanediamine, N-cyclohexyl-N'-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethyl-3H-imidazo[4,5-b]pyridin-7-yl]- (9CI) (CA INDEX NAME)



RN 332141-56-7 HCAPLUS
CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethyl-3H-imidazo[4,5-b]pyridin-7-yl]-N'-[2-(3,4-dimethoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 332141-58-9 HCAPLUS
CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethyl-3H-imidazo[4,5-b]pyridin-7-yl]-N'-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 332141-79-4 HCAPLUS
CN 1,2-Ethanediamine, N-cyclopentyl-N'-[2,5-dimethyl-3-(2,4,6-trimethylphenyl)-2H-pyrazolo[4,3-b]pyridin-7-yl]- (9CI) (CA INDEX NAME)



RN 332141-80-7 HCAPLUS
CN 1,2-Ethanediamine, N-cyclohexyl-N'-[2,5-dimethyl-3-(2,4,6-trimethylphenyl)-2H-pyrazolo[4,3-b]pyridin-7-yl]- (9CI) (CA INDEX NAME)



RN 332141-81-8 HCAPLUS
CN 1,2-Ethanediamine, N-[2-(3,4-dimethoxyphenyl)ethyl]-N'-[2,5-dimethyl-3-(2,4,6-trimethylphenyl)-2H-pyrazolo[4,3-b]pyridin-7-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 332141-83-0 HCAPLUS
CN 1,2-Ethanediamine, N-[2,5-dimethyl-3-(2,4,6-trimethylphenyl)-2H-pyrazolo[4;3-b]pyridin-7-yl]-N'-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 332141-89-6 HCAPLUS
CN 1,2-Ethanediamine, N-cyclopentyl-N'-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethyl-2H-pyrazolo[4,3-b]pyridin-7-yl]- (9CI) (CA INDEX NAME)



RN 332141-90-9 HCAPLUS
CN 1,2-Ethanediamine, N-cyclohexyl-N'-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethyl-2H-pyrazolo[4,3-b]pyridin-7-yl]- (9CI) (CA INDEX NAME)



RN 332141-91-0 HCAPLUS
CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethyl-2H-pyrazolo[4,3-b]pyridin-7-yl]-N'-[2-(3,4-dimethoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 332141-92-1 HCAPLUS
CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethyl-2H-pyrazolo[4,3-b]pyridin-7-yl]-N'-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 332141-97-6 HCAPLUS
CN 1,2-Ethanediamine, N-cyclopentyl-N'-[1,5-dimethyl-3-(2,4,6-trimethylphenyl)-1H-pyrazolo[4,3-b]pyridin-7-yl]- (9CI) (CA INDEX NAME)



RN 332141-98-7 HCAPLUS
CN 1,2-Ethanediamine, N-cyclohexyl-N'-[1,5-dimethyl-3-(2,4,6-trimethylphenyl)-1H-pyrazolo[4,3-b]pyridin-7-yl]- (9CI) (CA INDEX NAME)



RN 332141-99-8 HCAPLUS
CN 1,2-Ethanediamine, N-[2-(3,4-dimethoxyphenyl)ethyl]-N'-[1,5-dimethyl-3-(2,4,6-trimethylphenyl)-1H-pyrazolo[4,3-b]pyridin-7-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 332142-00-4 HCAPLUS
CN 1,2-Ethanediamine, N-[1,5-dimethyl-3-(2,4,6-trimethylphenyl)-1H-pyrazolo[4,3-b]pyridin-7-yl]-N'-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 332142-05-9 HCAPLUS
CN 1,2-Ethanediamine, N-cyclopentyl-N'-[3-(2,6-dichloro-4-methoxyphenyl)-1,5-dimethyl-1H-pyrazolo[4,3-b]pyridin-7-yl]- (9CI) (CA INDEX NAME)



RN 332142-06-0 HCAPLUS
CN 1,2-Ethanediamine, N-cyclohexyl-N'-[3-(2,6-dichloro-4-methoxyphenyl)-1,5-dimethyl-1H-pyrazolo[4,3-b]pyridin-7-yl]- (9CI) (CA INDEX NAME)



RN 332142-07-1 HCAPLUS
CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-1,5-dimethyl-1H-pyrazolo[4,3-b]pyridin-7-yl]-N'-[2-(3,4-dimethoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 332142-08-2 HCAPLUS
CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-1,5-dimethyl-1H-pyrazolo[4,3-b]pyridin-7-yl]-N'-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 332142-13-9 HCAPLUS
CN 1,2-Ethanediamine, N-cyclopentyl-N'-[5-methyl-3-(2,4,6-trimethylphenyl)-3H-1,2,3-triazolo[4,5-b]pyridin-7-yl]- (9CI) (CA INDEX NAME)



RN 332142-14-0 HCAPLUS
CN 1,2-Ethanediamine, N-cyclohexyl-N'-[5-methyl-3-(2,4,6-trimethylphenyl)-3H-1,2,3-triazolo[4,5-b]pyridin-7-yl]- (9CI) (CA INDEX NAME)



RN 332142-15-1 HCAPLUS
CN 1,2-Ethanediamine, N-[2-(3,4-dimethoxyphenyl)ethyl]-N'-[5-methyl-3-(2,4,6-trimethylphenyl)-3H-1,2,3-triazolo[4,5-b]pyridin-7-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 332142-16-2 HCAPLUS
CN 1,2-Ethanediamine, N-[5-methyl-3-(2,4,6-trimethylphenyl)-3H-1,2,3-triazolo[4,5-b]pyridin-7-yl]-N'-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 332142-21-9 HCAPLUS
CN 1,2-Ethanediamine, N-cyclopentyl-N'-[3-(2,6-dichloro-4-methoxyphenyl)-5-methyl-3H-1,2,3-triazolo[4,5-b]pyridin-7-yl]- (9CI) (CA INDEX NAME)



RN 332142-22-0 HCAPLUS
CN 1,2-Ethanediamine, N-cyclohexyl-N'-[3-(2,6-dichloro-4-methoxyphenyl)-5-methyl-3H-1,2,3-triazolo[4,5-b]pyridin-7-yl]- (9CI) (CA INDEX NAME)



RN 332142-23-1 HCAPLUS
CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-5-methyl-3H-1,2,3-triazolo[4,5-b]pyridin-7-yl]-N'-[2-(3,4-dimethoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 332142-24-2 HCAPLUS
CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-5-methyl-3H-1,2,3-triazolo[4,5-b]pyridin-7-yl]-N'-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 332142-45-7 HCAPLUS
CN 2H-Imidazo[4,5-b]pyridin-2-one, 7-[[2-(cyclopentylamino)ethyl]amino]-1,3-dihydro-1,5-dimethyl-3-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)



RN 332142-46-8 HCAPLUS
CN 2H-Imidazo[4,5-b]pyridin-2-one, 7-[[2-(cyclohexylamino)ethyl]amino]-1,3-dihydro-1,5-dimethyl-3-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)



RN 332142-47-9 HCAPLUS
CN 2H-Imidazo[4,5-b]pyridin-2-one, 7-[[2-[[2-(3,4-dimethoxyphenyl)ethyl]amino]ethyl]amino]-1,3-dihydro-1,5-dimethyl-3-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 332142-48-0 HCAPLUS
CN 2H-Imidazo[4,5-b]pyridin-2-one, 1,3-dihydro-1,5-dimethyl-7-[[2-[[1-(2-pyrimidinyl)-4-piperidinyl]amino]ethyl]amino]-3-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 332142-53-7 HCAPLUS
CN 2H-Imidazo[4,5-b]pyridin-2-one, 7-[[2-(cyclopentylamino)ethyl]amino]-3-(2,6-dichloro-4-methoxyphenyl)-1,3-dihydro-1,5-dimethyl- (9CI) (CA INDEX NAME)



RN 332142-54-8 HCAPLUS
CN 2H-Imidazo[4,5-b]pyridin-2-one, 7-[[2-(cyclohexylamino)ethyl]amino]-3-(2,6-dichloro-4-methoxyphenyl)-1,3-dihydro-1,5-dimethyl- (9CI) (CA INDEX NAME)



RN 332142-55-9 HCAPLUS
CN 2H-Imidazo[4,5-b]pyridin-2-one, 3-(2,6-dichloro-4-methoxyphenyl)-7-[[2-[[2-(3,4-dimethoxyphenyl)ethyl]amino]ethyl]amino]-1,3-dihydro-1,5-dimethyl- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 332142-56-0 HCAPLUS
CN 2H-Imidazo[4,5-b]pyridin-2-one, 3-(2,6-dichloro-4-methoxyphenyl)-1,3-dihydro-1,5-dimethyl-7-[[2-[[1-(2-pyrimidinyl)-4-piperidinyl]amino]ethyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 332890-16-1 HCAPLUS
CN 1,2-Ethanediamine, N-[2,6-dimethyl-1-(2,4,6-trimethylphenyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]-N'-(tetrahydro-2H-pyranyl)- (9CI) (CA INDEX NAME)





RN 332890-19-4 HCAPLUS
CN 1,2-Ethanediamine, N-[1-(2,6-dichloro-4-methoxyphenyl)-2,6-dimethyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-N'-(tetrahydro-2H-pyranyl)- (9CI) (CA INDEX NAME)



RN 332890-30-9 HCAPLUS
CN 1,2-Ethanediamine, N-[3,6-dimethyl-1-(2,4,6-trimethylphenyl)-1H-pyrazolo[3,4-b]pyridin-4-yl]-N'-(tetrahydro-2H-pyranyl)- (9CI) (CA INDEX NAME)





RN 332890-34-3 HCAPLUS
CN 1,2-Ethanediamine, N-[1-(2,6-dichloro-4-methoxyphenyl)-3,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl]-N'-(tetrahydro-2H-pyranyl)- (9CI) (CA INDEX NAME)



RN 332890-38-7 HCAPLUS
CN 1,2-Ethanediamine, N-[2,6-dimethyl-1-(2,4,6-trimethylphenyl)-3H-imidazo[4,5-b]pyridin-7-yl]-N'-(tetrahydro-2H-pyranyl)- (9CI) (CA INDEX NAME)



RN 332890-42-3 HCAPLUS
CN 1,2-Ethanediamine, N-[1-(2,6-dichloro-4-methoxyphenyl)-2,6-dimethyl-3H-imidazo[4,5-b]pyridin-7-yl]-N'-(tetrahydro-2H-pyranyl)- (9CI) (CA INDEX NAME)



RN 332890-54-7 HCAPLUS
CN 1,2-Ethanediamine, N-[2,5-dimethyl-3-(2,4,6-trimethylphenyl)-2H-pyrazolo[4,3-b]pyridin-7-yl]-N'-(tetrahydro-2H-pyranyl)- (9CI) (CA INDEX NAME)





RN 332890-58-1 HCAPLUS
CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethyl-2H-pyrazolo[4,3-b]pyridin-7-yl]-N'-(tetrahydro-2H-pyranyl)- (9CI) (CA INDEX NAME)



RN 332890-63-8 HCAPLUS
CN 1,2-Ethanediamine, N-[1,5-dimethyl-3-(2,4,6-trimethylphenyl)-1H-pyrazolo[4,3-b]pyridin-7-yl]-N'-(tetrahydro-2H-pyranyl)- (9CI) (CA INDEX NAME)





RN 332890-67-2 HCAPLUS
CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-1,5-dimethyl-1H-pyrazolo[4,3-b]pyridin-7-yl]-N'-(tetrahydro-2H-pyranyl)- (9CI) (CA INDEX NAME)



RN 332890-70-7 HCAPLUS
CN 1,2-Ethanediamine, N-[5-methyl-3-(2,4,6-trimethylphenyl)-3H-1,2,3-triazolo[4,5-b]pyridin-7-yl]-N'-(tetrahydro-2H-pyranyl)- (9CI) (CA INDEX NAME)





RN 332890-74-1 HCAPLUS
CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-5-methyl-3H-1,2,3-triazolo[4,5-b]pyridin-7-yl]-N'-(tetrahydro-2H-pyranyl)- (9CI) (CA INDEX NAME)



RN 332890-82-1 HCAPLUS
CN 2H-Imidazo[4,5-b]pyridin-2-one, 1,3-dihydro-1,5-dimethyl-7-[[2-[(tetrahydro-2H-pyranyl)amino]ethyl]amino]-3-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)





RN 332890-84-3 HCAPLUS
CN 2H-Imidazo[4,5-b]pyridin-2-one, 3-(2,6-dichloro-4-methoxyphenyl)-1,3-dihydro-1,5-dimethyl-7-[[2-[(tetrahydro-2H-pyranyl)amino]ethyl]amino]- (9CI) (CA INDEX NAME)





IT **252063-62-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of certain alkylene diamine-substituted heterocycles as NPY1 receptor inhibitors)
RN 252063-62-0 HCAPLUS
CN 3-Indolizinecarboxylic acid, 2-amino-1-(2,4,6-trimethylphenyl)-, ethyl ester (9CI) (CA INDEX NAME)